Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine

There is a myriad of diseases that plague the world ranging from infectious, cancer and other chronic diseases with varying interventions. However, the dynamism of causative agents of infectious diseases and incessant mutations accompanying other forms of chronic diseases like cancer, have worsened...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2024-05, Vol.29 (11), p.2584
Main Authors: Egwu, Chinedu O, Aloke, Chinyere, Onwe, Kenneth T, Umoke, Chukwunalu Igbudu, Nwafor, Joseph, Eyo, Robert A, Chukwu, Jennifer Adaeze, Ufebe, Godswill O, Ladokun, Jennifer, Audu, David Tersoo, Agwu, Anthony O, Obasi, David Chukwu, Okoro, Chukwuemeka O
Format: Article
Language:English
Subjects:
Animals
Aprepitant
Bioavailability
Cancer
Chronic diseases
Communicable diseases
controlled-release
Drug Delivery Systems
Drug dosages
Drug resistance
Drugs
Health aspects
Humans
infectious diseases
Ligands
Medicine
Nabilone
Nanomedicine - methods
Nanoparticles
Nanostructures - chemistry
Nanotechnology
Nanotechnology - methods
Neoplasms - drug therapy
Oncology, Experimental
Patient compliance
Pharmaceutical industry
Publishing industry
Retention
Review
targeted-delivery
Tizanidine
Toxicity
treatment
Vehicles
Verteporfin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a myriad of diseases that plague the world ranging from infectious, cancer and other chronic diseases with varying interventions. However, the dynamism of causative agents of infectious diseases and incessant mutations accompanying other forms of chronic diseases like cancer, have worsened the treatment outcomes. These factors often lead to treatment failure via different drug resistance mechanisms. More so, the cost of developing newer drugs is huge. This underscores the need for a paradigm shift in the drug delivery approach in order to achieve desired treatment outcomes. There is intensified research in nanomedicine, which has shown promises in improving the therapeutic outcome of drugs at preclinical stages with increased efficacy and reduced toxicity. Regardless of the huge benefits of nanotechnology in drug delivery, challenges such as regulatory approval, scalability, cost implication and potential toxicity must be addressed via streamlining of regulatory hurdles and increased research funding. In conclusion, the idea of nanotechnology in drug delivery holds immense promise for optimizing therapeutic outcomes. This work presents opportunities to revolutionize treatment strategies, providing expert opinions on translating the huge amount of research in nanomedicine into clinical benefits for patients with resistant infections and cancer.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules29112584